Regenxbio Inc
RGNX11.210USD
+0.040+0.36%
收盘 11/07, 16:00（美东）报价延迟15分钟
567.44M总市值
亏损市盈率 TTM
关于 Regenxbio Inc 公司
REGENXBIO Inc. 是一家临床阶段的生物技术公司，致力于通过基因治疗的治愈潜力改善生活。该公司利用其专有的腺相关病毒 (AAV) 基因治疗交付平台 (NAV 技术平台) 开发了一系列基因治疗项目，以治疗遗传疾病。该公司专注于三个领域的内部开发管线：视网膜、神经肌肉和神经退行性疾病。其研究性 AAV 疗法包括 ABBV-RGX-314、RGX-202 和 RGX-121。该公司正在与 AbbVie 合作开发 ABBV-RGX-314，以治疗受湿性老年性黄斑变性、糖尿病视网膜病变 (DR) 和其他以视力丧失为特征的慢性视网膜疾病影响的大量患者群体。该公司正在开发 RGX-202 来治疗杜氏肌营养不良症 (Duchenne)。该公司正在开发 RGX-121 用于治疗 II 型粘多糖贮积症 (MPS II)，这是一种进行性神经退行性溶酶体贮积症。
Regenxbio Inc简介
公司代码RGNX
公司名称Regenxbio Inc
上市日期Sep 17, 2015
CEOMr. Curran M. Simpson
员工数量353
证券类型Ordinary Share
年结日Sep 17
公司地址9804 Medical Center Drive
城市ROCKVILLE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编20850
电话12405528181
网址https://regenxbio.com/
公司代码RGNX
上市日期Sep 17, 2015
CEOMr. Curran M. Simpson
Regenxbio Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-55.17%
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
53.97K
-8.33%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
20.06K
+63.21%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
19.05K
+68.83%
Mr. George V. Migausky
Mr. George V. Migausky
Independent Director
Independent Director
19.05K
+68.83%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
17.59K
-1.31%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
16.11K
-48.81%
Mr. Allan M. Fox, J.D.
Mr. Allan M. Fox, J.D.
Director
Director
--
--
Dr. David C. (Dave) Stump, M.D.
Dr. David C. (Dave) Stump, M.D.
Independent Director
Independent Director
--
--
Dr. A. N. (Jerry) Karabelas, Ph.D.
Dr. A. N. (Jerry) Karabelas, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-55.17%
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
53.97K
-8.33%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
20.06K
+63.21%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
19.05K
+68.83%
Mr. George V. Migausky
Mr. George V. Migausky
Independent Director
Independent Director
19.05K
+68.83%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
17.59K
-1.31%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 11月8日 周六
更新时间: 11月8日 周六
持股股东
股东类型
持股股东
持股股东
占比
Redmile Group, LLC
9.43%
BlackRock Institutional Trust Company, N.A.
8.43%
The Vanguard Group, Inc.
6.59%
Fox (Allan Mark)
5.73%
JP Morgan Asset Management
5.16%
其他
64.66%
持股股东
持股股东
占比
Redmile Group, LLC
9.43%
BlackRock Institutional Trust Company, N.A.
8.43%
The Vanguard Group, Inc.
6.59%
Fox (Allan Mark)
5.73%
JP Morgan Asset Management
5.16%
其他
64.66%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
33.94%
Investment Advisor
31.21%
Hedge Fund
12.74%
Individual Investor
7.62%
Research Firm
6.92%
Pension Fund
0.28%
Bank and Trust
0.26%
Family Office
0.26%
Private Equity
0.06%
其他
6.73%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
403
44.05M
87.32%
-5.71M
2025Q2
421
48.19M
95.62%
-3.63M
2025Q1
446
48.46M
96.35%
-3.90M
2024Q4
444
48.16M
97.22%
-4.82M
2024Q3
444
49.64M
100.43%
-4.45M
2024Q2
437
49.30M
99.98%
-3.20M
2024Q1
451
48.23M
99.21%
+414.63K
2023Q4
436
43.62M
98.84%
-7.14M
2023Q3
439
43.73M
99.56%
-6.26M
2023Q2
439
43.86M
100.57%
-5.31M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Redmile Group, LLC
4.78M
9.45%
-19.06K
-0.40%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.27M
8.45%
+348.80K
+8.90%
Jun 30, 2025
The Vanguard Group, Inc.
3.42M
6.77%
-51.80K
-1.49%
Jun 30, 2025
Fox (Allan Mark)
2.90M
5.74%
+7.77K
+0.27%
May 30, 2025
JP Morgan Asset Management
2.99M
5.91%
+38.82K
+1.32%
Jun 30, 2025
State Street Investment Management (US)
1.84M
3.65%
+777.55K
+72.93%
Jun 30, 2025
BlackRock Financial Management, Inc.
1.73M
3.43%
+637.97K
+58.36%
Jun 30, 2025
Goldman Sachs & Company, Inc.
1.61M
3.18%
+962.62K
+149.64%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.13M
2.23%
+21.57K
+1.95%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.12M
2.22%
-24.96K
-2.17%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
WisdomTree BioRevolution Fund
1.92%
iShares Neuroscience and Healthcare ETF
0.79%
Virtus LifeSci Biotech Clinical Trials ETF
0.68%
Global X Genomics & Biotechnology ETF
0.51%
JPMorgan Fundamental Data Science Small Core ETF
0.32%
ALPS Medical Breakthroughs ETF
0.29%
SPDR S&P Biotech ETF
0.16%
Direxion Daily S&P Biotech Bull 3X Shares
0.09%
iShares Health Innovation Active ETF
0.09%
Fidelity Enhanced Small Cap ETF
0.08%
查看更多
WisdomTree BioRevolution Fund
占比1.92%
iShares Neuroscience and Healthcare ETF
占比0.79%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.68%
Global X Genomics & Biotechnology ETF
占比0.51%
JPMorgan Fundamental Data Science Small Core ETF
占比0.32%
ALPS Medical Breakthroughs ETF
占比0.29%
SPDR S&P Biotech ETF
占比0.16%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.09%
iShares Health Innovation Active ETF
占比0.09%
Fidelity Enhanced Small Cap ETF
占比0.08%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
